Takeda's U.S. Sales Decline Make It Fall Short Of Double-Profit Forecast
This article was originally published in PharmAsia News
Executive Summary
Takeda Pharmaceutical, by not making a major acquisition during the April-September period, realized an 88 percent increase in pretax profit